trauma. musculoskeletal sysytem and connective tissue diseases
Conditions
Interventions
Intervention 1: Intervention group :administration of oxicodone 10mg/peroral and acetaminophen 1 gram intravenously and 5 cc streile waterintravenously as placebo and evaluation of pain score and sid
60 of study. Intervention 2: Control Group: Administration of 5 mg Morphine sulfate and oral placebo, after 0, 10, 30, 60 minutes pain score and side effects will be evaluated.
Treatment - Drugs
Intervention group :administration of oxicodone 10mg/peroral and acetaminophen 1 gram intravenously and 5 cc streile waterintravenously as placebo and evaluation of pain score and side effects in min
60 of study.
Control Group: Administration of 5 mg Morphine sulfate and oral placebo, after 0, 10, 30, 60 minutes pain score and side effects will be evaluated.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: signing informed consent by the participate in the study; age greater than 16 and less than 50 years old; moderate to severe pain caused by trauma (pain score above 5 on the visual Analog scale) and trauma to extremities without head trauma. Exclusion criteria: history of allergy or intolerance to morphine sulphate or oxycodone; concurrent substance abuse; mild to moderate pain (pain score of less than 5); psychiatric disorders; patients with history of chronic obstructive pulmonary disease, asthma, and ischemic heart disease; reduction in the patient's level of consciousness (GCS score less than 15 ); patients with low blood pressure (systolic blood pressure less than 90 mmHg); patients with liver dysfunction and pneumothorax.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain control. Timepoint: At the begining, 10, 30 and 60 minutes after the administration of the study medications. Method of measurement: Pain score by asking from patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effects and changes in vital signs. Timepoint: At the begining, 10, 30 and 60 minutes after the administration of the study medications. Method of measurement: Monitoring the patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohamad Amin Zare
Tehran University of Medical Sciences
Outcome results
None listed